Actively Recruiting
Combined Personalized Tumor Neoantigen Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC After First-line Treatment
Led by The First Affiliated Hospital of Nanchang University · Updated on 2024-12-30
10
Participants Needed
2
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a combined treatment approach for patients with advanced non-small cell lung cancer NSCLC who have progressed after first-line treatment. This study aims to assess the effectiveness and safety of a personalized tumor neoantigen-based peptide vaccine combined with a PD-1 inhibitor and radiotherapy. Key outcomes include objective response rate, disease control rate, adverse events, progression-free survival, and overall survival. Participants will receive a personalized radiotherapy course followed by PD-1 inhibitor injections every three weeks. Alongside, they will be given 10 subcutaneous injections of the personalized vaccine over a 21-week treatment period. The vaccine administration is divided into a primary phase with six treatments spaced weekly and biweekly, and a boost phase with four treatments spaced three weeks apart. During the study, participants will undergo regular follow-up visits every six weeks until the study ends, including blood collection, physical exams, performance status assessments, imaging scans CTMRI and X-rays, and laboratory tests. Researchers will monitor treatment response, safety, and survival outcomes over an average of 30 weeks, with progression-free and overall survival assessed up to 66 months. The total study duration supports comprehensive evaluation of the treatment combination.
CONDITIONS
Brief Title
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
Research Team
Y
Yong Li, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here